Literature DB >> 2261907

Follicular and Hürthle cell carcinoma of the thyroid.

D S Cooper1, C R Schneyer.   

Abstract

Follicular and Hürthle cell thyroid cancers account for about one fifth of thyroid cancers in the United States. Diagnosis can be difficult, despite the use of fine needle biopsy, and surgery is often necessary to make a definitive diagnosis. Total thyroidectomy is the treatment of choice, and in the case of follicular cancer, radioiodine ablation is usually performed. Distant metastatic disease can also be treated with radioiodine. For Hürthle cell tumors, radioiodine therapy is unlikely to be beneficial.

Entities:  

Mesh:

Year:  1990        PMID: 2261907

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  10 in total

1.  Comparison of prognostic scoring systems in follicular thyroid cancer.

Authors:  K W Teo; N K Yuan; W B Tan; R Parameswaran
Journal:  Ann R Coll Surg Engl       Date:  2017-07       Impact factor: 1.891

2.  Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?

Authors:  H Chen; T L Nicol; M A Zeiger; W C Dooley; P W Ladenson; D S Cooper; M Ringel; S Parkerson; M Allo; R Udelsman
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

3.  Expression of ICAM-1 in distant metastatic thyroid carcinoma.

Authors:  J M Fernández-Real; C Villabona; M Fernández-Castañer; E Sagarra; J M Gómez-Saéz; J Soler
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

4.  Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.

Authors:  Danielli Matsuura; Avery Yuan; Laura Wang; Rohit Ranganath; Dauren Adilbay; Victoria Harries; Snehal Patel; Michael Tuttle; Bin Xu; Ronald Ghossein; Ian Ganly
Journal:  Thyroid       Date:  2022-03       Impact factor: 6.506

5.  Disease severity and radioactive iodine use for thyroid cancer.

Authors:  M R Haymart; D G Muenz; A K Stewart; J J Griggs; M Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2013-01-15       Impact factor: 5.958

6.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

7.  Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.

Authors:  S Jang; X-M Yu; S Odorico; M Clark; R Jaskula-Sztul; C M Schienebeck; K R Kupcho; A D Harrison; G N Winston-McPherson; W Tang; H Chen
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

8.  Hürthle cell carcinoma in an autonomous thyroid nodule in an adolescent.

Authors:  A R Siddiqui; S Karanauskas
Journal:  Pediatr Radiol       Date:  1995

9.  Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.

Authors:  Samuel Jang; Xiao-Min Yu; Celina Montemayor-Garcia; Kamal Ahmed; Eric Weinlander; Ricardo V Lloyd; Ajitha Dammalapati; David Marshall; James R Prudent; Herbert Chen
Journal:  Oncotarget       Date:  2017-04-11

10.  High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas.

Authors:  T Takano; A Miyauchi; H Yoshida; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.